Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RA2708 | Tofacitinib | 0.3 | uM | 2 | MCP-1 (MCAF) | 87.0 | 65 | ||||
| RA2708 | 2 | MCP-1 (MCAF) | 98.5 | 42 | |||||||
| RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 200.0 | 59 | |
| RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 1178.5 | 44 | |
| N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 451.5 | 38 | |
| N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 516.0 | 50 | |
| RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 187.0 | 53 | |
| RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 391.0 | 45 | |
| RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 4967.0 | 58 | |
| RA2159 | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 5750.0 | 39 | ||||
| N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 4226.0 | 42 | |
| N2645 | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 5041.5 | 48 | ||||
| RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 3227.0 | 56 | |
| RA2708 | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 3686.0 | 36 | ||||
| RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 33.0 | 63 | |
| RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 105.0 | 48 | |
| N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 136.0 | 45 | |
| N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 375.0 | 49 | |
| RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 51.0 | 48 | |
| RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 408.0 | 35 | |
| RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 4543.0 | 55 | |
| RA2159 | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 4600.5 | 58 | ||||
| N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 3917.0 | 43 | |
| N2645 | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 3722.5 | 36 | ||||
| RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 3854.5 | 34 |